Riitta Lassila on LMWH Benefits in COVID19
Riitta Lassila, Professor of Coagulation Medicine at University of Helsinki, shared on LinkedIn:
”We are happy to report RDW benefits from early high risk (the same for corona disease progression and thrombosis) – targeted LMWH prophylaxis initiated at outpatient setting.
The two first virus waves when vaccination program had only started.
Lessons for any future severe viral outbursts.”
Read the full article here.
Article: Early outpatient use of low-molecular-weight heparin benefits COVID-19 outcome in association with hospitalization – Lessons learned
Authors: Miika Koskinen, Eeva Ruotsalainen, Mia Wallin, Hilkka Kivelä, Kerstin Carlsson, Jari Petäjä, Eero Hirvensalo, Markku Mäkijärvi, Riitta Lassila
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 17, 2026, 15:55Mostafa Faisal Mohammed Saleh: Evidence-Based Recommendations for Hodgkin Lymphoma Management in LMICs
-
Mar 17, 2026, 15:50Yogesh Kalkonde: Advancing Sickle Cell Care Through Primary Health Training
-
Mar 17, 2026, 15:49Melissa Hollo: Closing the Gap in Maternal Anemia Care Through HerCare
-
Mar 17, 2026, 15:46Simon Senanu: Rouleaux Formation – When Red Cells Stack Like Coins
-
Mar 17, 2026, 15:45Heghine Khachatryan: Hidden Hematologic Causes of Cryptogenic Stroke
-
Mar 17, 2026, 15:45Wolfgang Miesbach: Six Years of Normal Factor VIII After a Single Gene Therapy in Hemophilia A
-
Mar 17, 2026, 15:44Jan Sloves: Venous Phasicity and the Role of IVC Mechanics
-
Mar 17, 2026, 15:43How Clinicians Navigate the Challenge of Balancing Clotting and Bleeding in CAD – Vasculearn Network
-
Mar 17, 2026, 15:41Beverly G. Tchang: Lipid-Lowering Therapy in Women During Pregnancy and Lactation